NLR — LLMpedia

NLR
Name	NLR
Other names	Neutrophil-to-lymphocyte ratio
Purpose	Marker of systemic inflammation and prognostic indicator
Specimen	Peripheral blood
Method	Complete blood count with differential
Units	Ratio (unitless)

Contents

NLR

NLR is a laboratory index derived from peripheral blood counts used as an indicator of systemic inflammation and host immune status. It is employed across clinical contexts from oncology to cardiology and critical care, and has been evaluated in large cohort studies and randomized trials involving institutions such as Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Cleveland Clinic, and Karolinska Institutet. Prominent clinicians and researchers associated with NLR literature include investigators from Harvard Medical School, Stanford University School of Medicine, University of Oxford, University of Cambridge, and Imperial College London.

Definition and Overview

NLR is defined as the ratio of the absolute neutrophil count to the absolute lymphocyte count measured in peripheral venous blood obtained for a complete blood count at centers like Mayo Clinic Laboratories and Quest Diagnostics. Historically, observations linking leukocyte patterns to outcomes were reported in studies from institutions including Johns Hopkins School of Medicine, University of Pennsylvania, UCLA, Duke University Medical Center, and Columbia University Irving Medical Center. NLR has been compared with other prognostic biomarkers such as the C-reactive protein measurement, erythrocyte sedimentation rate assays, and composite scores developed at Mount Sinai Hospital and Brigham and Women's Hospital.

Biologically, NLR reflects interplay among innate and adaptive immune elements characterized by neutrophil activation pathways studied at National Institutes of Health, Institut Pasteur, Max Planck Institute for Infection Biology, and Salk Institute. Lymphocyte dynamics involving subsets described in research from Pierre and Marie Curie University, Weizmann Institute of Science, University of Toronto, and Cold Spring Harbor Laboratory influence the denominator. Studies of inflammatory signaling pathways referencing NF-κB and cytokine networks have been conducted by groups at Fred Hutchinson Cancer Center, Roche, GlaxoSmithKline, and Pfizer laboratories. Pathophysiologic mechanisms linking NLR to outcomes have been explored in translational programs at Beth Israel Deaconess Medical Center, Vanderbilt University Medical Center, and University of Michigan.

NLR is calculated by dividing absolute neutrophil count by absolute lymphocyte count from automated hematology analyzers produced by manufacturers like Sysmex Corporation, Beckman Coulter, Abbott Laboratories, and Siemens Healthineers. Pre-analytical considerations follow guidelines from organizations such as Clinical and Laboratory Standards Institute and laboratory services at APHL and UKAS-accredited sites. Large multicenter datasets from National Health Service trusts, Veterans Health Administration, and cohort studies like Framingham Heart Study and UK Biobank have provided methodological standards for reporting.

Reported cutoffs vary by population and condition; oncology consortia at ESMO and ASCO and cardiology guideline bodies like AHA and ESC have cited thresholds often between 2 and 5 in prognostic models. Population studies from Centers for Disease Control and Prevention, National Health Service (England), Statistics Canada, and cohort analyses at Kaiser Permanente and All of Us Research Program inform age-, sex-, and ethnicity-specific distributions. Interpretation is context-dependent—for example, perioperative risk assessments at Johns Hopkins Hospital versus long-term prognostic models in registry data from EuroSCORE and RECORD studies.

NLR is influenced by acute infections documented in surveillance programs at World Health Organization and seasonal variations noted by public health agencies such as CDC and European Centre for Disease Prevention and Control. Medications (e.g., corticosteroids used in protocols at Mayo Clinic and immunotherapies from National Cancer Institute trials), hematologic disorders treated at MD Anderson Cancer Center, and procedures performed at Cleveland Clinic can confound values. Comorbid conditions reported in registries from Veterans Affairs and global health datasets from World Bank and WHO further limit specificity. Analytical variability across instruments from Beckman Coulter and Siemens is documented in multicenter quality assessments led by College of American Pathologists.

Ongoing research at institutions such as Imperial College London, University of Oxford, Stanford Medicine, Harvard T.H. Chan School of Public Health, Johns Hopkins Bloomberg School of Public Health, and industry partnerships with Novartis, Roche, and AstraZeneca explores NLR integration with genomic markers from 1000 Genomes Project, proteomic signatures from Human Proteome Organization, and imaging biomarkers from Radiological Society of North America datasets. Machine learning studies published by teams at Google Health, DeepMind, MIT CSAIL, and IBM Research seek to combine NLR with electronic health record-derived scores from Epic Systems and Cerner to improve prognostication. Multinational trials coordinated by WHO and consortia including Global Alliance for Genomics and Health are assessing NLR as a stratification tool in adaptive trial designs.

Category:Laboratory tests